630404-09-0Relevant articles and documents
DIHYDROOXADIAZINONES
-
Page/Page column 227; 237, (2019/02/15)
The present invention provides dihydrooxydiazinone compounds of general formula (I) : in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.
DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS
-
Page/Page column 103, (2010/09/18)
The object of the present invention is benzothiazine derivatives having the capability of inhibiting 11β-HSD1 not only at an enzymatic level but also at a cell level. The compounds of the present invention are of general formula (I). Wherein notably R1 represents a hydrogen or OR1 represents an ester or an ether. R2 represents a naphthyl or a 1, 2, 3, 4-tetrahydro-naphthalene or a biphenyl or phenyl pyridine or a substituted phenyl. R3 represents a methyl or ethyl; R4 and R'4 represent a hydrogen.
DIHYDROIMIDAZOTHIAZOLE DERIVATIVES
-
Page/Page column 57, (2008/06/13)
Compounds of formula (I): or pharmaceutically acceptable salts thereof, exhibit 5-HT1A agonism in addition to noradrenaline reuptake inhibition and optionally also 5-HT reuptake inhibition are useful for the treatment of obesity.
IMIDAZOLIUM CXCR3 INHIBITORS
-
Page 10-11, (2008/06/13)
Imidazolium compounds of formula (I); wherein: Aˉ is an anion; R1, R2 and R3 are the same or different and are hydrogen, C1-C6 alkyl, aryl, fused aryl, or heteroaryl; or are substituted aryl, fused ar